Imugene Financial Statements From 2010 to 2025
| IUGNF Stock | USD 0.23 0.01 4.55% |
Check Imugene financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Imugene's main balance sheet or income statement drivers, such as , as well as many indicators such as . Imugene financial statements analysis is a perfect complement when working with Imugene Valuation or Volatility modules.
Imugene |
Imugene Limited Company Profit Margin Analysis
Imugene's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Imugene Profit Margin | (2.92) % |
Most of Imugene's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Imugene Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Imugene Limited has a Profit Margin of -2.9198%. This is 73.95% lower than that of the Healthcare sector and 87.32% lower than that of the Biotechnology industry. The profit margin for all United States stocks is 129.91% higher than that of the company.
Imugene Limited Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Imugene's current stock value. Our valuation model uses many indicators to compare Imugene value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Imugene competition to find correlations between indicators driving Imugene's intrinsic value. More Info.Imugene Limited is rated fourth overall in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Imugene's earnings, one of the primary drivers of an investment's value.About Imugene Financial Statements
Imugene stakeholders use historical fundamental indicators, such as Imugene's revenue or net income, to determine how well the company is positioned to perform in the future. Although Imugene investors may analyze each financial statement separately, they are all interrelated. For example, changes in Imugene's assets and liabilities are reflected in the revenues and expenses on Imugene's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Imugene Limited. Please read more on our technical analysis and fundamental analysis pages.
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia. Imugene is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Imugene Pink Sheet
Imugene financial ratios help investors to determine whether Imugene Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Imugene with respect to the benefits of owning Imugene security.